Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | FURIN | P09958 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | CA9 | Q16790 | 6/20 | 0.35 |
| ▸ | CA7 | P43166 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KHK | P50053 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL8003545 | 0.81 | ITGB3 (0.50) | SLC18A3USP2MEN1KMT2A | |
| SCHEMBL7346450 | 0.76 | ITGB3 (0.45) | SLC18A3KDM4EALDH1A1FURINCA2 | |
| SCHEMBL7346457 | 0.76 | ITGB3 (0.45) | SLC18A3KDM4EALDH1A1FURINCA2 | |
| SCHEMBL7342452 | 0.73 | SLC18A3 (0.50) | SLC18A3KDM4EKHK | |
| SCHEMBL7342460 | 0.73 | SLC18A3 (0.50) | SLC18A3KDM4EKHK | |
| SCHEMBL7342448 | 0.73 | SLC18A3 (0.50) | SLC18A3KDM4EKHK | |
| SCHEMBL6839450 | 0.68 | ITGB3 (0.65) | KDM4EALDH1A1FURINMEN1KMT2A | |
| Methane SCHEMBL7337948 | 0.68 | ITGB3 (0.64) | KDM4EALDH1A1FURINMEN1KMT2A | |
| SCHEMBL7343409 | 0.67 | ITGB3 (0.42) | KDM4EALDH1A1FURINCA2CA9 | |
| Hydrochloric Acid SCHEMBL8431413 | 0.67 | ALOX15 (0.64) | KDM4EALDH1A1FURINMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030118584-A1 | Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | disclosed |
| US-20020177172-A1 | RESTORATION OF PLATELET AGGREGATION BY ANTIBODY ADMINISTRATION AFTER GPIIB/IIIA ANTAGONIST TREATMENT | WESTERN MICHIGAN UNIVERSITY | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118584-A1 | Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment | F13B, GP6, FGB | SLC18A3 2450/4885KDM4E 4175/4885ALDH1A1 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.